A Study of LY3866288 in Healthy Participants

Inclusion Criteria: * Females must be of nonchildbearing potential or of childbearing potential and agree to use contraception * Males must either be infertile via bilateral orchiectomy or vasectomized at least 90 days prior to screening with proper documentation * Body mass index (BMI) between 18.5 and 32.0 kilogram per square meter (kg/m²) * In good general health, determined by no clinically significant findings from medical history, physical examination, 12 lead electrocardiogram (ECGs), vital signs measurements, or clinical laboratory evaluations at screening and/or check-in as assessed by the investigator (or designee) Exclusion Criteria: * Females only: Are lactating or pregnant * Any history or presence of disease(s), deemed clinically significant: * Dermatological disease * Liver disease * Metabolic disease, including congenital nonhemolytic hyperbilirubinemia (e.g., Gilbert syndrome) * Gastrointestinal disease, including peptic ulcer disease, active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug, or gastric reduction surgery. Note: participants with a history of appendectomy and/or inguinal hernia repairs will be acceptable * Biliary disease, including cholecystectomy * Cancer within the past 5 years (except localized basal cell, squamous, or in situ cancer of the skin) * History or current evidence of ophthalmic disorder, such as central serous retinopathy or retinal vein occlusion, active wet age-related macular degeneration, diabetic retinopathy with macular edema, uncontrolled glaucoma, corneal pathology such as keratitis, keratoconjunctivitis, keratopathy, corneal abrasion, inflammation or ulceration * Clinically significant, active cardiovascular disease or history of myocardial infarction within 6 months prior to first dose, or 12-lead ECG abnormalities that are clinically significant at screening * History of alcohol and/or drug abuse within 2 years prior to screening * Have been on a diet incompatible with the on-study diet, in the opinion of the investigator (or designee), and as confirmed by the sponsor, within the 30 days prior to Day 1 and throughout * Use of tobacco, smoking cessation products, products containing nicotine, or e-cigarettes (nicotine and non-nicotine) within 90 days prior to screening and throughout